574 related articles for article (PubMed ID: 16034881)
1. Metformin monotherapy for type 2 diabetes mellitus.
Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
[TBL] [Abstract][Full Text] [Related]
2. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
5. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
[TBL] [Abstract][Full Text] [Related]
6. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
7. [Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis].
Sáenz Calvo A; Fernández Esteban I; Mataix Sanjuán A; Ausejo Segura M; Roqué M; Moher D
Aten Primaria; 2005 Sep; 36(4):183-91. PubMed ID: 16153370
[TBL] [Abstract][Full Text] [Related]
8. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2011 Jun; (6):CD008143. PubMed ID: 21678374
[TBL] [Abstract][Full Text] [Related]
9. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
[TBL] [Abstract][Full Text] [Related]
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Palmer SC; Mavridis D; Nicolucci A; Johnson DW; Tonelli M; Craig JC; Maggo J; Gray V; De Berardis G; Ruospo M; Natale P; Saglimbene V; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque L; Lloyd A; Ahmad N; Liu Y; Tiv S; Wiebe N; Strippoli GF
JAMA; 2016 Jul; 316(3):313-24. PubMed ID: 27434443
[TBL] [Abstract][Full Text] [Related]
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
13. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
14. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
[TBL] [Abstract][Full Text] [Related]
15. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
Bolen S; Feldman L; Vassy J; Wilson L; Yeh HC; Marinopoulos S; Wiley C; Selvin E; Wilson R; Bass EB; Brancati FL
Ann Intern Med; 2007 Sep; 147(6):386-99. PubMed ID: 17638715
[TBL] [Abstract][Full Text] [Related]
16. [The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2].
Vuković M; Lapcević M; Kalezić N; Gvozdenović BS
Srp Arh Celok Lek; 2007; 135(7-8):447-52. PubMed ID: 17929538
[TBL] [Abstract][Full Text] [Related]
17. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression.
Baumeister H; Hutter N; Bengel J
Cochrane Database Syst Rev; 2012 Dec; 12():CD008381. PubMed ID: 23235661
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis.
Monami M; Lamanna C; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Feb; 79(2):196-203. PubMed ID: 17931733
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]